![1]()
News
PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF
September 14, 2021
The SGLT2 inhibitor dapagliflozin boosted KCCQ scores and 6-minute walk distance in HFpEF patients in a 324-patient randomized trial.
News
Study gives bleeding risk estimates for VTE patients on anticoagulants
September 13, 2021
New research provides best available estimates of long-term bleeding risk with different anticoagulants, authors say.
News
Growing proportion of cardiac arrests in U.S. considered opioid related
September 10, 2021
Due to a steep rise, opioid-associated cardiac arrests have become a major public health issue.
![1]()
News
Two swings, two misses with colchicine, Vascepa in COVID-19
September 1, 2021
The study cohorts varied from healthcare and public workers at high risk for infection to individuals already hospitalized with COVID-19.
![1]()
News
EMPEROR-Preserved spouts torrent of reports on empagliflozin treatment of HFpEF
August 31, 2021
The primary report from EMPEROR-Preserved on using empagliflozin to treat patients with HFpEF arrived with four other analyses published in its wake.
![1]()
News
Dapagliflozin in HFrEF may cut arrhythmias, sudden death: DAPA-HF
August 27, 2021
Response to the positive findings was tempered, however, by the post hoc nature of the analysis, choice of primary outcome, and inconsistencies between key subgroups.
![1]()
News
ICMs detect serious arrhythmias in high-risk post-MI patients: SMART-MI
August 27, 2021
In patients with modestly reduced left ventricular ejection fraction after MI, implantable monitors detect many times more arrhythmias than usual care, the SMART-MI trial showed.
![1]()
News
Optimizing screening for asymptomatic Afib
August 27, 2021
How can we optimize screening for patients with asymptomatic atrial fibrillation (Afib)?
![1]()
News
EMPEROR-Preserved: Empagliflozin scores HFpEF breakthrough
August 27, 2021
Empagliflozin is the first treatment to produce an unequivocal, hard-endpoint benefit in patients with heart failure with preserved ejection fraction, a practice-changing result.
![1]()
News
ACE-I or ARB therapy in patients with low eGFR
August 26, 2021
Is it safe to continue angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) therapy in patients whose estimated glomerular filtration rate (eGFR) has decreased to below 30 mL/min per 1.73 m2?
